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The ECM consists primarily of collagenous and microfibrillar 
elastic  polymers,  their  associated  adaptor  molecules,  and   
hydrophilic proteoglycans that together assemble into complex 
multiprotein structures (Hynes, 2009; Ramirez and Rifkin, 
2009). These extracellular macroaggregates of similar composi-
tion but distinct tissue-specific morphologies provide cell sup-
port, organize individual tissues, impart structural integrity, 
and orchestrate cell behavior through interactions with a vari-
ety of cell surface receptors. Recently, it has become apparent 
that the ECM is also a dynamic modulator of growth factor 
bioavailability and signaling (Ramirez and Rifkin, 2003, 2009; 
Hynes, 2009).
Fibrillins are major components of the ECM and form   
either microfibrils or, together with tropoelastin, elastic assem-
blies (Ramirez and Sakai, 2010). Additionally, fibulins and latent 
TGF-–binding proteins (LTBPs), molecules structurally related to 
fibrillins, are crucial elements of nascent microfibril assemblies. 
The instructive function of fibrillin assemblies is mediated pri-
marily by bound TGF- and BMP (Ramirez and Rifkin, 2009). 
TGF- is usually released from cells as a large latent complex   
(LLC) consisting of TGF-, the TGF- propeptide (latency- 
associated  protein),  and  an  LTBP  (Annes  et  al.,  2003;  Rifkin, 
2005). The LLC is targeted to microfibrils by noncovalent inter-
action between specific domains of fibrillin-1 and -2 and LTBP. 
The release and/or activation of TGF- from ECM-sequestered 
LLC enables ligand–receptor binding (Annes et al., 2003; Kang 
et al., 2009). BMPs, which are members of the TGF- family and 
are intimately involved in connective tissue modeling and remod-
eling,  also  assemble  noncovalently  with  fibrillins  (Sengle   
et al., 2008a), but BMP–propeptide association does not prevent 
the ligand from interacting with its receptors (Sengle et al., 2008b).   
The demonstration that fibrillin-1 mutations perturb trans-
forming growth factor (TGF)– bioavailability/signaling in 
Marfan syndrome (MFS) changed the view of the extra-
cellular matrix as a passive structural support to a dynamic   
modulator of cell behavior. In this issue, Nistala et al. (2010.   
J.  Cell  Biol.  doi:  10.1083/jcb.201003089)  advance 
this concept by demonstrating how fibrillin-1 and -2 reg-
ulate TGF- and bone morphogenetic protein (BMP)   
action during osteoblast maturation.
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Interaction with fibrillins targets BMPs to the ECM, from which 
they are subsequently released, and probably protects BMPs from 
neutralization by soluble inhibitors.
Insight into the function of fibrillin-1 and -2 has derived 
from the study of two genetic diseases, MFS and congenital con-
tractural arachnodactyly (CCA). MFS is caused by mutations in 
fibrillin-1 and is associated with both structural and regulatory 
deficits of microfibrillar assemblies in multiple tissues (Judge 
and Dietz, 2008). Fibrillin-1 mutations impair tissue integrity 
by perturbing formation of microfibrillar assemblies, thereby 
promoting improper LLC sequestration and, consequently, in-
discriminant activation of latent TGF- (Neptune et al., 2003; 
Habashi et al., 2006). This concept that fibrillin-1 modulates the 
specificity of growth factor action also extends to fibrillin-2.   
Mutations in fibrillin-2 cause CCA, a condition akin to but clini-
cally distinct from MFS (Putnam et al., 1995). In addition to re-
capitulating the human phenotype, Fbn2
/ mice display a bone 
patterning defect caused by reduced BMP signaling in the in-
terdigital mesenchyme (Arteaga-Solis et al., 2001). The unique 
phenotypes of MFS and CCA and their distinct TGF- and BMP 
signaling abnormalities support the notion that the fibrillins have 
discrete regulatory properties in spite of both being part of the same 
ECM macroaggregate and both binding TGF- and BMP.
In this issue, Nistala et al. identify fibrillin microfibrils as 
extrinsic factors that impart regulatory specificity to TGF- and 
BMP signals. The authors addressed the question of how fibrillin-1   
or -2 regulates TGF- and BMP signaling during osteogenic 
differentiation, as both MFS and CCA display decreased bone 
mineral density. Both cytokines are abundant in the bone matrix 
but are known to exert opposing actions on osteoblast maturation 
(Fig.1 A). Using Fbn2-null mice and osteoblasts, the authors 
show that bone formation and osteoblast maturation are impaired. 
Furthermore, cultured osteoblasts from these mice form fewer 
mineralized nodules because of decreased levels of both the tran-
scription factor osterix and osterix-driven stimulation of collagen I 
deposition. BMP restores osterix and collagen expression and, 
consequently, ECM mineralization in the mutant cultures. Latent 
TGF- is inappropriately activated by Fbn2
/ osteoblasts, and 
the inhibition of TGF- signaling enhances maturation of the 
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that microfibrils function in a tissue-specific rather than in a 
universally predictable manner. The mechanistic basis for this 
remains unknown.
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mutant osteoblasts (Fig. 1 C). These findings demonstrate that 
fibrillin-2 microfibrils normally restrict TGF- signaling during   
osteoblast maturation.
In contrast, Fbn1
/ osteoblasts express more osterix and 
collagen and mature more rapidly than control cells (Fig. 1 B). 
As with Fbn2
/ cells, latent TGF- is inappropriately activated 
in Fbn1
/ cultures, which additionally display augmented 
BMP signaling associated with reduced ligand sequestration 
in the ECM. These findings suggest that the elevation of osteo-
inductive BMP signals in Fbn1
/ osteoblast cultures overrides 
the inhibitory action of improper TGF- activity. As such, the 
results identify fibrillin-1 microfibrils as negative regulators of 
TGF- and BMP bioavailability in the forming bone.
These  observations  support  several  important  conclu-
sions. First, the sum rather than the relative amounts of TGF-  
and  BMP  signaling  determines  the  rate  of  bone  formation. 
Both Fbn1- and Fbn2-null cells display enhanced signaling 
by TGF-, an inhibitor of osteoblast maturation, but the level 
of BMP, a potent osteoinductive factor, modifies the final out-
come. Second, microfibril association with TGF- and BMP 
complexes operates both positively by concentrating the sig-
naling molecules (Arteaga-Solis et al., 2001) or negatively by 
restricting the activity of the protein (Nistala et al., 2010b). 
Third,  cytokine-directed  changes  in  osteoblasts  affect  their 
coupling with osteoclast-degradative activities. These same in-
vestigators have found that increased latent TGF- activation is   
responsible for enhanced osteoblast-supported osteoclasto-
genesis by Fbn1
/ and Fbn2
/ cells through the elevation of re-
ceptor activator of NF-B ligand (RANKL) production (Fig. 1;   
Nistala et al., 2010a). Thus, fibrillin-1 and -2 microfibrils 
control  both  anabolic  and  catabolic  phases  of  bone  homeo-
stasis and perhaps lineage determination of marrow stem cells.   
Finally, organ-specific manifestations of MFS and CCA suggest 
Figure 1.  Fibrillin control of bone metabolism. (A) Fibrillin-1 and -2 deposition in bone matrix controls active TGF- and BMP levels, yielding appropriate 
osteoblastogenesis and osteoblast-supported osteoclastogenesis. (B) Fibrillin-1 loss heightens active TGF- and free BMP concentrations, mildly accelerating 
osteoblast maturation. Increased TGF- signaling also stimulates osteoblast production of RANKL, thereby increasing matrix degradation by osteoclasts.   
(C) Fibrillin-2 loss maintains normal BMP levels and raises active TGF- levels, yielding decreased osteoblast maturation and increased osteoblast-supported 
osteoclastogenesis. Thus, bone anabolism and catabolism are both integral parts of fibrillin-modulated TGF- and BMP signaling.951 Bone matrix to growth factors • Rifkin and Todorovic
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